steatotic liver disease
Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases
Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)